The trade group says the denial does not settle its concerns about a law that limits minors' access to supplements marketed for weight loss or muscle building, and the case now returns to district court.
|Articles|February 21, 2013
Expo West Sneak Peak: PhosphoLean NOPE+EGCG
Hear from Chemi Nutra about this potential appetite suppressant.
Advertisement
Learn about Chemi Nutra’s PhosphoLean ingredient at Engredea 2013. PhosphoLean NOPE + EGCG is a patented appetite suppressant compound that is clinically proven to help people stay on their diets, says the company. The ingredient reportedly blend signals the brain to switch off the sensations of hunger and helps individuals manage their stressful diets and lower diet depression. Stop by the Chemi Nutra booth and learn how PhosphoLean can be a keynote ingredient for your next weight management product.
Booth: 138
Advertisement
Related to this article
Women are the predominant users of these drugs, and the authors say guidance has not kept pace, with nutrient gaps and supplement support also in focus.
Trade groups say the law's broad criteria could restrict access to supplements with uses beyond weight loss or muscle building.
At The Outlook on Active Nutrition, Doug Kalman, PhD, RD, FISSN, outlines where GLP-1 drugs are falling short, and where nutraceutical brands can step in.
Advertisement
Advertisement
Trending on Nutritional Outlook - Supplement, Food & Beverage Manufacturing Trends
1
Monterey Nutra Brings Mushroom Chocolate, Smoothie, and Coffee Concepts to SupplySide Global
2
Givaudan to Reveal New Metabolic Health Botanical at SupplySide Global 2026
3
Beyond the Symptom: How Botanicals Are Redefining the Sleep Health Category
4
Omega-3 Supply, Not Price, Is the Real Threat
5